SCHEMBL4838875

SCHEMBL4838875

CCN(C(=O)C(CC(=O)NOC(c1ccccc1)(c1ccccc1)c1ccccc1)CC(=O)OC(C)(C)C)c1ccc(-c2ccccn2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.34
GPR88 Q9GZN0 8/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
UGT1A1 P22309 2/20 0.32
MLNR O43193 1/20 0.32
NR1I2 O75469 1/20 0.32
SLCO2B1 O94956 1/20 0.32
ABCB11 O95342 1/20 0.32
ABCB1 P08183 1/20 0.32
CCKAR P32238 1/20 0.32
OPRK1 P41145 1/20 0.32
GHSR Q92847 1/20 0.32
SLCO1B3 Q9NPD5 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
SLCO1B1 Q9Y6L6 1/20 0.32
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840333 0.87 CA2 (0.35) GPR88CA2CA9CYP3A4CYP2C9
SCHEMBL4840808 0.87 CA2 (0.35) GPR88CA2CA9OPRK1CYP3A4
SCHEMBL4841280 0.85 GPR88 (0.37) GPR88CA2CA9ABCB1ABCG2
SCHEMBL4835720 0.83 MCHR1 (0.36) CA2CA9CYP3A4
SCHEMBL4831400 0.82 CYP3A4 (0.38) GPR88CA2CA9CYP3A4CYP2C9
SCHEMBL4838858 0.80 CA2 (0.39) TRPV1CA2CA9UGT1A1MLNR
SCHEMBL4841415 0.76 HDAC3 (0.39) CYP2C9SLC6A9
SCHEMBL4838181 0.75 CYP3A4 (0.36) CA2CA9ABCB1CYP3A4CYP2C9
SCHEMBL4838038 0.75 USP2 (0.39)
SCHEMBL4837207 0.75 CYP3A4 (0.44) CA2CA9CYP3A4CYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD TRPV1 4650/4885GPR88 953/4885CA2 333/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD TRPV1 4672/4885GPR88 964/4885CA2 344/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH TRPV1 4685/4885GPR88 965/4885CA2 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.